EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials

Kusha A Mohammadi, Taylor Brackin, Gregory G Schwartz, Philippe Gabriel Steg, Michael Szarek, Garen Manvelian, Robert Pordy, Sergio Fazio, Gregory P Geba iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.6310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Kusha A Mohammadi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Neoplasms, PCSK9 Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Assess the risk of new and worsening cancer events among participants who received the lipid‐lowering therapy alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor.

Design

Pooled post hoc analysis.

Setting

Six phase 3 or phase 4 placebo‐controlled randomised trials with alirocumab.

Participants

A total of 24,070 patients from the safety population with complete dosing data (alirocumab, n = 12,533; placebo, n = 11,537).

Intervention

Alirocumab 75 mg, alirocumab 150 mg, alirocumab 75 mg increasing to 150 mg if low‐density lipoprotein cholesterol

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalNeoplasmsPCSK9 InhibitorsHumansCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsRisk AssessmentSubtilisinsTreatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

LDL-CPCSK9 inhibitoralirocumabcholesterolincident cancerserum lipids

Substanzen

Antibodies, MonoclonalCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsSubtilisinsPCSK9 InhibitorsalirocumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
  • University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Université Paris-Cité, Paris, France.
  • FACT (French Alliance for Cardiovascular Trials) INSERM U1148, Paris, France.
  • Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.
  • State University of New York, Downstate School of Public Health, Brooklyn, New York, USA.

ORCID-Profile: Gregory P Geba

Förderung

  • Regeneron Pharmaceuticals

Zitieren

APA

Mohammadi, K. A., Brackin, T., Schwartz, G. G., Steg, P. G., Szarek, M., Manvelian, G., Pordy, R., Fazio, S., & Geba, G. P. (2023). Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Medicine. https://doi.org/10.1002/cam4.6310

Vancouver

Mohammadi KA, Brackin T, Schwartz GG, Steg PG, Szarek M, Manvelian G, et al. Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Medicine. 2023. doi:10.1002/cam4.6310

BibTeX
@article{Mohammadi2023,
  author = {Mohammadi, Kusha A and Brackin, Taylor and Schwartz, Gregory G and Steg, Philippe Gabriel and Szarek, Michael and Manvelian, Garen and Pordy, Robert and Fazio, Sergio and Geba, Gregory P},
  title = {Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6310}
}
Kostenlos starten →